Betta Pharmaceuticals

Betta Pharmaceuticals

World Rank (Jan-05-2024)
4,431
Market Cap (Jan-05-2024)
2.948 Billion USD
World Rank (Jul-30-2023)
4,045
Market Cap (Jul-30-2023)
3.333 Billion USD
World Rank (Jan-07-2022)
3,256
Market Cap (Jan-07-2022)
5.064 Billion USD
World Rank (Jan-01-2021)
2,306
Market Cap (Jan-01-2021)
6.790 Billion USD
Company Rank in Country in 2023
Rank in China in July-2023 is 723
Headquarters Country
China
Market Cap (Mar-08-2026)
2.78
Employee Count
1,466
Employee Count as of Date
As on 2020
World Region
Asia
World Subregion
Eastern Asia
Annual Revenue in USD
352 Million USD
Annual Net Income in USD
60 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
984 Million USD
Total Liabilities in USD
268 Million USD
Total Equity in USD
716 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Company Website
BETTA PHARMACEUTICALS
Yahoo
Yahoo @ Shenzhen
Company Profile
Betta Pharmaceuticals is a senior executive team for innovative drug discovery and commercialization company mainly forced on drug development for cancer, diabetes and other major diseases that seriously affect human health. It is having more than 30 innovative drug projects in Betta’s pipeline with 15 in clinical stages, including 4 in phase III clinical trials. The company annual revenue is 284.1 million USD and 1,466 employee as on 2020. The headquarters is in China.
Stock Exchange
Shenzhen
Company SubCategory
Top Healthcare Companies in China

Share